Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.64 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620345 | 0.85 | PIK3CA (0.74) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 | |
| SCHEMBL3877305 | 0.85 | PIK3CG (0.78) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 | |
| SCHEMBL1621649 | 0.83 | PIK3CA (0.72) | PIK3CA | |
| SCHEMBL1651188 | 0.81 | PIK3CG (0.80) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 | |
| SCHEMBL3804150 | 0.81 | PIK3CG (0.80) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 | |
| SCHEMBL1651874 | 0.81 | PIK3CG (1.00) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 | |
| SCHEMBL12850665 | 0.81 | ABL1 (0.62) | PIK3CGPIK3CACYP3A4ABL1 | |
| SCHEMBL14735787 | 0.80 | PIK3CA (0.68) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 | |
| SCHEMBL1621507 | 0.80 | SMO (0.68) | PIK3CGPIK3CACYP3A4 | |
| SCHEMBL1653742 | 0.80 | PIK3CG (0.78) | PIK3CGPIK3CADYRK1AFSCN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | PIK3CG 5/4885PIK3CA 1/4885DYRK1A 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.